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Abstract
Adjusting for baseline variables that are prognostic for the outcome can improve
precision of estimated marginal treatment effects in randomized trials, thus improving
power for a fixed sample size or reducing the required sample size to achieve a desired
power.
We compare the statistical properties of the estimated marginal treatment effect
derived from the analysis of covariance and unadjusted estimators when we pre- vs.
post-select baseline variables using several variable selection procedures within the
context of an on-going Alzheimer’s Disease (AD). Our simulation studies mimic the
on-going HOPE4MCI trial, whose goal is to reduce cognitive decline in patients with
amnestic mild cognitive impairment due to AD. We used two curated datasets from
the ADNI study representing weakly and strongly prognostic baseline variables for
the outcome to pre- or post-select baseline variables for use in hypothetical trials to
which these pre- or post-selected variables were applied. We consider several baseline
variable selection procedures including always adjusting for the baseline outcome
only, adjusting for all 21 pre-specified candidate baseline variables, and adjusting for
variables selected from a proposed cross-validated R2 procedure (CV −R2), the lasso
or VSURF (random forest) procedures.
All of our estimators had similar and small bias, and the corresponding confidence
intervals produced roughly 95% coverage of the marginal treatment effect.Adjusting
for prognostic baseline variables selected from the CV -R2, lasso and RF procedures,
as well as including all candidate baseline variables, resulted in large reductions in the
required sample size when compared to the unadjusted estimator (roughly 15 to 30%
reduction). Selecting baseline variables using the lasso procedure resulted in adjusted
marginal treatment effects with the largest precision gains. When baseline variables
are not prognostic, the lasso resulted in approximately no loss of precision.
ii
We recommend baseline variable adjustment within randomized trials where there
are prognostic baseline variables. The baseline variable selection procedure should be
pre-planned including when and how baseline variables are selected. Post-selecting
baseline variables using the lasso procedure resulted in the largest precision gain
when baseline variables are prognostic for the outcome and small loss of precision
when baseline variables are not prognostic.
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1 Introduction
We focus on the context of a randomized controlled trial (RCT) comparing a treatment
to control with the goal of estimating the marginal treatment effect. While an
unadjusted estimator of the marginal treatment effect is simple to implement and
unbiased, the estimator disregards potential information in the baseline variables.
Adjusting for baseline variables that are correlated with the outcome can improve,
i.e. increase, the precision of the estimated marginal treatment effect (1-8 ).
Adjusting for baseline variables within RCTs has been a much discussed topic (9-
10 ). Reviews of RCTs have found that only 24% to 34% of trials adjust for baseline
variables in the analysis (11-14 ). In 2010, the Consolidated Standards of Reporting
Trials (CONSORT) provided clarity surrounding study methods, like baseline variable
adjustment, for RCTs (15 ). They suggested “...an adjusted analysis may be sensible,
especially if one or more variables is thought to be prognostic”, “the decision to adjust
should not be determined by whether baseline differences are statistically significant”
and “adjusted analyses should be specified in the study protocol” (p. 14).
Although an extensive literature exists on a multitude of estimators for the marginal
treatment effect that adjust for baseline variables and the large sample properties of
these estimators (8, 16-20 ), there has been less guidance on what procedure to use
to select baseline variables for use with these estimators. Our work is motivated by
the ongoing HOPE4MCI trial (21 ). The primary objective of the trial is to assess the
efficacy of a drug, AGB101, compared to a placebo on slowing cognitive decline in
patients with amnestic mild cognitive impairment (MCI) due to Alzheimer’s disease
(AD).
While planning the trial, the statistical analysis plan was developed including
specification of which baseline variables are to be included in the estimation of the
marginal treatment effect for the primary outcome. However, the question remains of
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whether the selection procedure, i.e. pre-selecting baseline variables for adjustment,
was optimal in the sense of maximizing the potential precision gain for the marginal
treatment effect. As an alternative, baseline variables could be post-selected, i.e.
identified during the analysis of the RCT data. The differences in these two approaches
have not been evaluated to the best of our knowledge.
Further, regardless of when (pre or post) the baseline variables are selected, there
are multiple baseline variable selection methods, but a lack of guidance as to which
is preferred. A wide range of classical variable selection methods exist, such as
stepwise, forward, and backward selection procedures. More recently there has been
rapid development in modern machine learning based variable selection methods.
Machine learning methods, such as lasso regression, have been used to estimate the
marginal treatment effect (23-28 ). Bloniarz et al.(2016) evaluated properties of the
baseline covariate adjusted marginal treatment effect derived under the randomization
inference framework, which differs from the superpopulation inference framework used
here. They showed that first using the cross-validated lasso (CV lasso) for variable
selection followed by fitting a linear model with ordinary least squares regression for
estimation, can substantially reduce the mean squared error (MSE) in estimating
the marginal treatment effect. Wager et al. (2016), using superpopulation inference,
proposed estimators of the marginal treatment effect using a CV lasso procedure and
a CV random forest procedure. The approaches by Bloniarz et al.(2016) and Wager
et al. (2016) resulted in substantial variance reductions compared to the unadjusted
estimator of the marginal treatment effect, i.e. difference in sample means. All of
these methods had similar confidence interval coverage probability.
Unlike the previously mentioned papers, Gagnon-Bartsch et al. (2020) make
use observational data from a previous study to try to increase the precision in
the estimated marginal treatment effect in a randomized trial, while guaranteeing
unbiasedness. They propose the reLOOP procedure. The first step is to apply a
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machine learning model, e.g. lasso regression or random forest, for the outcome given
baseline variables using the observational data (referred to as the remnant). the
remnant is then used to predict the outcomes for each individual in the RCT as
a function of their baseline variables. Then they generate a leave-one-out potential
outcome (LOOP) prediction under treatment and control for each individual by fitting
treatment-group specific models for the outcome as a function of baseline variables
and the predicted outcome from the remnant, using the data from the N-1 remaining
individuals (which leads to unbiasedness). These models can be fit by any method
ranging from linear regression to random forests.
We use the context of the HOPE4MCI trial to systemically evaluate the impact
of when and how the baseline variables are selected for covariate adjustment. In
all cases, the selected baseline variables will be used in a linear regression model of
the outcome given treatment and baseline variables that is fit with ordinary least
squares to estimate the marginal treatment effect using the analysis of covariance
(ANCOVA) method. The timing of the variable selection can be either pre-trial
(called pre-selection) or based on the data accrued at the end of the trial (called post-
selection). In all cases, the variable selection is based on evaluating how prognostic
the baseline variables are for the outcome (and not on how imbalanced the baseline
variables are across arms). The paper is organized as follows. In the next section, we
provide notation and definitions followed by descriptions of several variable selection
procedures. In sections 3 and 4, we describe and provide results from an extensive
simulation study motivated by the HOPE4MCI trial. In the discussion, we summarize
our findings and provide future areas of research.
3
2 Methods
2.1 Notation and Definitions
We assume a randomized controlled trial where we observe n independent participants,
each with data vector (Wi, Ai, Yi) from an unknown probability distribution P , where
Wi is a m× 1 column vector of baseline variables, Ai is the treatment arm indicator
(Ai ∈ 0, 1 where 1= treatment and 0= control), and Yi is a continuous valued outcome.
We assume no missing values. We assume 1:1 randomization so that treatment and
placebo was assigned by the binary treatment arm indicator, A, by taking a draw from
a Bernoulli distribution with probability 1/2. Thus the treatment arm is assigned
independently of the baseline variables. The select baseline variables, W , can be
continuous, binary, or categorical variables. The treatment effect of interest is the
average or marginal treatment effect:
ψ = E(Y |A = 1) − E(Y |A = 0).
We estimate ψ using the analysis of covariance (ANCOVA) estimator. The ANCOVA
estimator of the marginal treatment effect adjusts for chance imbalance between the
treatment arms in baseline variables. The ANCOVA estimator is the coefficient for
treatment from the following linear regression model regressing the outcome Y on the
treatment arm indicator A and main terms for baseline variables W :
E[Y |A,W ] = β0 + β1A+ β2W1 + ...+ βm+1Wm. (1)
The estimate of ψ is ˆ︁β1 obtained via ordinary least squares (OLS). Yang and Tsiatis
(2001) showed that the ANCOVA estimator is consistent, even when the linear
regression model is arbitrarily misspecified.
For the remainder of the paper, we use the ANCOVA estimator for the marginal
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treatment effect due to its simplicity. However, there are alternatives to the this
estimator that have favorable properties beyond consistency, e.g. Rotnitzky et al
(2012) proposed a doubly robust estimator that is asymptotically guaranteed to be
as precise or more precise than the unadjusted estimator. See (8 ) for a comparison
of several additional estimators.
2.2 Pre/Post selection of variables for inclusion in ANCOVA
estimator
Figure 1: We can pre-select or post-select baseline variables. If variables are pre-selected,
identify a set of potentially prognostic variables to choose from the available trial planning
data and select m baseline variables during the planning phase. Using the trial data in
the analysis phase, estimate the marginal treatment effect adjusting for the m prognostic
baseline variables chosen in the trial planning phase. If variables are post-selected, identify
a set of potentially prognostic variables to choose from the available trial planning data
during the planning phase. Using the trial data in the analysis phase, select the m prognostic
variables and estimate the marginal treatment effect adjusting for the m prognostic baseline
variables chosen in the analysis stage.
Typically, the baseline variables to be included in the ANCOVA estimator are
pre-selected, i.e., selected before the trial. We also consider here the case where they
are post-selected, i.e., selected at the end of the trial based on data collected in the
5
trial. Figure 1 shows the difference between pre- and post-selection. In both cases,
we assume a common set of M candidate baseline variables that may be selected for
inclusion in the vector W used in the ANCOVA estimator. The candidate list of
variables would typically be constructed based on clinical knowledge, previous data
sets, and relevant existing literature.
When we pre-select W , it is based on a separate, pre-existing dataset (e.g., from
an observational study or trial involving the same population) that contains both Y
and the initial set of M candidate baseline variables. A variable selection procedure is
applied to that previous dataset to select m < M baseline variables that will be named
in the analysis plan for the trial. At the conclusion of the trial, the marginal treatment
effect is estimated by ANCOVA that adjusts for the pre-specified m variables in the
ANCOVA estimator.
An alternative is to post-select the m baseline variables using the data in the
trial itself. Here, while planning the trial, the set of M candidate baseline variables
would be identified, again based on existing knowledge of the relationship between Y
and the M candidate baseline variables, and the analysis plan would be developed,
including details of how the trial data will be used to select m of the M candidate
baseline variables for inclusion in the ANCOVA estimator. The number m of variables
included in the ANCOVA estimator is not fixed for the case of post-selection, since
it depends on the variables selection procedure’s output (which, in turn, depends on
the trial data).
2.3 Variable Selection Procedures
Regardless of the timing of the selection of the baseline variables, we use a variable




We refer to the first procedure as the cross-validated R2 (CV -R2) procedure. It
involves a structured search over candidate subsets W of the M baseline variables,
where additional baseline variables are included if they increase the estimated relative
efficiency of the unadjusted estimator by a non-negligible amount.
For a candidate subset W of the M baseline variables, we estimate the additional
variation in Y that can be explained by W using OLS regression, beyond what can be
explained by A alone (19 ), called the R-squared. This estimate involves computing
the sum of squared residuals for Y based on estimates of the study arm specific mean
of Y , sm1 and sm0 for the treatment and control arms, respectively. Second, use
ordinary least squares regression separately by study arm (a ∈ 0, 1) to obtain the
model fit Qa(W,B(a)) for the linear regression model E(Y = 1|A = a,W ) = β0a +
β1aW1+...+βm,aWm where B(a) denotes the regression coefficients from the study arm
specific regression model. To approximate the relative reduction in required sample
size to achieve a desired power using the adjusted estimator (ANCOVA) compared
to the unadjusted estimator for the marginal treatment effect (38, 39 ), we define the
estimated R-squared as





To avoid being overly optimistic, we use a modified estimate of R-squared that
is similar to the above display except using a leave-one-out cross-validation (CV)
procedure. The leave-one-out CV is implemented by fitting sma and Qa(W,Ba) on
all the data except observation i. Then for each participant i, compute the squared
difference between Yi and the estimates of Qa(Wi, ˆ︁Ba) and ˆ︃sma and replace these in
the sums in the numerator and denominator, respectively, on the right side of (2).
The corresponding cross-validated estimator of the R-squared (2) is denoted by ˆ︃R2n
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instead of ˜︃R2n.
The CV -R2 baseline variable selection procedure is the following:
Step 1: Compute an estimate of ˆ︃R2n when adjusting for each of the M baseline
variables one at a time. Rank these from highest (largest R-squared) to lowest
(smallest R-squared).
Step 2: If the highest ranked variable has ˆ︃R2n ≤ 1n , then set the baseline variable
set to be empty, which is equivalent to using the unadjusted estimator.
Else, do a single pass over each candidate variable from highest to lowest rank
to determine which variables get selected. To do this, first initialize the current
variable set to be empty. Next, considering the candidate variables from highest to
lowest rank, include each candidate variable whose addition to the current variable
set increases the corresponding ˆ︃R2n by at least 1/n.
2.3.2 Lasso Variable Selection
Tibishirani (1996) proposed the least absolute shrinkage and selection operator (lasso)
regression, a popular machine learning technique for model selection based on a
set of candidate covariates. The goal of the lasso regression is to determine the
most important predictors to include for a reduced, parsimonious model. The lasso
regression includes a L1 penalty on the sum of the absolute value of the coefficients in
addition to the ordinary least squares (OLS) loss function (i.e. the sums of squared
residuals). As a result, some coefficients may be forced to 0 and discarded from the
model. Therefore, the variable selection process is embedded in the model due to
the L1 penalty. The lasso’s properties under linear regression, including consistent
coefficient estimates, have been established (36 ).
The geometry of the L1 penalty of the lasso creates the parsimonious model,
making the method popular in high-dimensional data analysis, especially when the
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number of covariates are larger than the sample size. In such settings, overfitting
can be present in linear regression based on OLS. Sometimes individuals conduct
model selection based on how imbalanced covariates are after randomization, leading
to incorrect inference (32 ). Lasso can mitigate these problems by performing variable
selection and avoiding overfitting (33 ). In addition, Tibshirani (1996) showed that
the lasso is more accurate and stable than traditional methods like the best subset
selections when there are small to moderate number of moderate-sized effects and a
large number of small effects. Hastie et al (2020) concluded that lasso gave better
accuracy than forward stepwise selection and best subset selection in low signal-to-
noise (SNR) range, and the relaxed lasso provided the highest accuracy in all SNR
levels (43 ).
2.3.3 Random Forest
Another popular machine learning technique for variable selection and building prediction
models is random forests (RF), first introduced by Breiman (2001). A RF is a
collection of classification or regression decision trees modeled off a randomly selected
training set and a subset of pre-specified predictor variables. Within each decision
tree, binary recursive partitioning is used to partition the covariate space such that the
mean of observations falling into a given partition defines the predicted value for the
outcome. Outcome predictions are determined by the aggregated results from a large
number of trees. Therefore, compared to a single decision tree, a RF typically provides
higher accuracy and maintains an interpretable relationship between the outcome
and predictors (38 ). A RF is able to perform variable selection by determining the
statistical characteristics of the optimal predictors, including accuracy of prediction
and variable importance, i.e. how often variables are included across the trees in the
forest and the improvement in prediction accuracy when they are selected. In this
way, similar to the lasso, a RF can determine the most important variables for a
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parsimonious and efficient model.
VSURF is a type of RF where variable selection is conducted by a two-step
algorithm (39 ). First, rank the variables in descending order by an averaged variable
importance (VI) over roughly 50 decision trees. Eliminate the unimportant variables
that do not exceed a certain variable importance threshold. Second, the algorithm
selects two subsets of variables: interpretation and prediction variables. For interpretation,
the algorithm computes a nested group of classification and regression trees and
ends with a group of variables that are all highly correlated with the outcome.
For prediction, a stepwise sequence of nested classification and regression trees are
constructed using the variables chosen in the interpretation step. The prediction step
leads to a smaller subset of variables that have minimal redundancy for prediction
purposes. We considered the subset of variables chosen in the prediction step as the
variables chosen by the VSURF algorithm.
3 Simulation Study
3.1 HOPE4MCI Trial
Our work is motivated by the HOPE4MCI clinical trial, the main objective of which
is to evaluate the efficacy of a the experimental drug, AGB101, on slowing cognitive
and functional impairment among patients with aMCI due to AD. Amnestic mild
cognitive impairment (aMCI) is classified as a clinical condition defined by memory
concerns and generally considered a transitional stage between normal aging and
AD dementia. Studies of patients with aMCI have reported aberrant activation of
the hippocampus, a structure critically important for episodic memory function (40-
42 ). The observed hippocampal hyperactivity is now considered a characteristic
feature of the aMCI stage of AD (43 ) and has been shown contribute to amyloid
accumulation (44-45 ) and is correlated with disease progression (46 ). Treatment
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with low dose Levetiracetam, an anti-seizure medication, has been shown to normalize
hippocampal dysfunction and improve memory function in patients with aMCI (42,
47 ). The HOPE4MCI study is designed to further examine if low dose Levetiracetam
can improve mild memory problems and slow progression of aMCI due to AD. The
trial uses the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score to quantify
impairment in cognitive function, where scores range from 0 to 18 with higher scores
indicating greater impairment. The primary outcome is the 18-month change in
CDR-SB score. Enrolled patients were required to be 55 to 85 years old, have a
baseline CDR-SB score of ≤ 2.5, and meet criteria for aMCI due to AD (48 ). The
target sample size was 160 participants and the hypothesized treatment effect was a
30% reduction in the mean 18-month change in CDR-SB comparing the treatment to
placebo arm, assuming the mean 18-month change in CDR-SB is 1.3 in the placebo
arm.
3.2 Trial planning data
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) database was used to curate
two datasets to aid in the design of the HOPE4MCI trial. The ADNI is a longitudinal
multicenter cohort study with observational data from cognitively normal older adults,
patients with MCI and patients with mild to moderate AD dementia. The longitudinal
data includes biochemical, clinical, genetic and imaging biomarkers for the detection
and prediction of AD progression. Both datasets were curated to match the inclusion
and exclusion criteria and duration of the HOPE4MCI Trial, i.e. provide baseline to
18-month follow-up with CDR-SB scores as well as a set of potentially prognostic
baseline variables. Specifically, at the time of selection, all participants with a
consensus diagnosis of MCI, aged between 55-85 at baseline, a Global CDR score of
0.5, a Mini-Mental Status Exam Score ≥ 24, and a CSF amyloid concentration ≤ 192
pg/ml, for which 24 months of cognitive and neuroimaging data was available, were
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identified. Key measures obtained from neuroimaging are used as secondary endpoints
in the HOPE4MCI trial, but were not considered for this manuscript. The resulting
dataset consisted of about 200 patients with MCI who met all criteria for entry into
the HOPE4MCI study with 2-year longitudinal clinical and neuropsychological data
available in the ADNI study. The available data was used to create two separate
datasets. The first dataset uses the 6-month ADNI visit as the study baseline. The
second dataset uses the baseline ADNI visit as the study baseline. The former
dataset represents a somewhat later stage of progression, and we are interested in
comparing the impact of different covariate-adjusted estimators using data generating
distributions from both datasets.
For both datasets, the following are the M candidate baseline variables: age,
gender, marriage status, divorce status, APOE4, CDR-SB score, Mini-Mental State
Examination (MMSE) score, Logical Memory Delayed Recall Score, Modified Hachinski
Total Score, Geriatric Depression Scale Total, Category Fluency (Animals) - Total
Correct, Trail Making Test Part A - Time to Complete, Trails A Errors of Commission,
Trail Making Test Part B - Time to complete, Trails B Errors of Commission, Trails
B Errors of Omission, Alzheimer’s Disease Assessment Scale- Cognition (ADAS Cog)
11 item score, ADAS Cog 13 Item score, Rey auditory verbal learning test (RAVLT)
Delay, RAVLT Recognition, and Functional Activities Questionnaire (FAQ). Descriptive
analysis of these two datasets revealed weaker correlations between the 18-month
change in CDR-SB scores and the above baseline variables in the first compared to
the second dataset. Below, we use the first and second ADNI datasets to represent
the settings where Y and W are weakly or strongly correlated, respectively.
3.3 Data generating distributions
We first consider the case where the baseline variables are pre-selected, i.e., selected
based only on a pre-trial data set. Below, we describe how we construct the following
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three scenarios:
D1) Y and W are weakly correlated (as in dataset 1)
D2) Y and W are strongly correlated (as in dataset 2)
D21) Y and W are strongly correlated pre-trial (as in dataset 2) but weakly
correlated in the trial itself (as in dataset 1).
To evaluate the performance of post-selecting the baseline variables, we considered
only D1 and D2 (since in this case it’s irrelevant what the pretrial data is).
In each scenario, we considered four simulation settings:
1) Baseline variables prognostic and no marginal treatment effect.
2) Baseline variables prognostic and positive marginal treatment effect.
3) Baseline variables not prognostic and no marginal treatment effect.
4) Baseline variables not prognostic and positive marginal treatment effect.
The positive marginal treatment effect is defined as a reduction in the 18-month
change in CDR-SB scores by 30% in the treatment arm compared to the control arm.
For each scenario-setting pair, we generated 10,000 simulated trials, each with
n = 160 participants, the target sample size of the HOPE4MCI trial. In all cases,
we first re-sampled vectors (W,Y ) (where here W is the full list of M candidate
baseline variables) with replacement from the appropriate ADNI dataset (depending
on D1, D2, D21). The reason is that we try to mimic the correlations from the
corresponding ADNI data sets, to make the simulations realistic. Next the treatment
arm indicator is assigned independent of the baseline variables, with probability 1/2
for treatment and placebo. The resulting data generating distribution corresponds to
baseline variables being prognostic for the outcome and to no treatment effect (setting
1). We next describe modifications that we made to define settings 2-4, which include
either/both of the following: (i) making the baseline variables not prognostic for (i.e.,
independent of) the outcome, and (ii) inducing a positive treatment effect.
For (i), nothing is changed for settings 1 and 2. In simulation settings 3 and 4,
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we create a distribution where the baseline variables are not prognostic by randomly
permuting the Y values among the trial participants. For (ii), in simulation settings
2 and 4, we induce a marginal treatment effect of 0.3 by replacing each treatment
arm participant’s value of Y by a 30% reduction defined as Y − 0.3 ∗ Y = 0.7Y .
In order to evaluate the performance of the methods that pre-select baseline
variables, prior to generating any simulated trials, we constructed a fixed, pre-trial
(planning) dataset for every combination of scenario (D1,D2,D21) and setting (1-4).
These datasets are based, roughly, on applying the aforementioned method to the
corresponding ADNI dataset. Specifically, for scenario D1 we started with ADNI
dataset 1; for D2 and D21 we started with ADNI dataset 2. Next, the treatment arm
indicator was assigned independently of the baseline variables, with probability 1/2,
to each participant. This corresponds to setting 1. To construct planning data sets for
scenarios 2-4, we make modifications described next. For simulation settings 3 and 4,
we randomly permuted the Y values among the participants. For simulation settings 2
and 4, we induced a marginal treatment effect of 0.3 by replacing each treatment arm
participant’s value of Y by a 30% reduction. Each scenario by setting combination
was generated one time with the full ADNI dataset 1 or 2. These are considered fixed.
Therefore, each baseline variable selection procedure for the pre-selection case needs
to be run only once for each scenario by setting combination.
We next describe the estimators and confidence interval procedures that we applied
to each simulated trial. For each simulated trial, we estimated the marginal treatment
effect using the unadjusted estimator and 5 ANCOVA estimators adjusting for the
following baseline variables, respectively:
A1) Baseline CDR-SB score only.
A2) All M candidate prognostic baseline variables.
A3) The m baseline variable selected via the CV -R2 procedure.
A4) The m baseline variables selected via the lasso regression procedure.
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A5) The m baseline variables selected via the RF procedure.
Confidence intervals were defined by: ˆ︂β1 ± 1.96 ∗ se(ˆ︂β1), with se(ˆ︂β1) denoting the
estimated standard error returned by the corresponding OLS linear regression model
fit for (1), computed as if the baseline variable set were fixed in advance (for all cases).
4 Simulation Results
4.1 Overall Findings
Tables 1-8 display the simulation study results. Regardless of when and which baseline
variables are selected, all estimators have similar and small bias and produced roughly
95% coverage of the marginal treatment effect, with coverage ranging from 92.8% to
95.3%. Further, the simulation results are similar under no or positive marginal
treatment effect.
We quantified the precision gain when using an adjusted estimator compared to the
unadjusted estimator by estimating the reduction in required sample size when using
the adjusted estimator compared to the unadjusted estimator with fixed power: 1 -
1/relative efficiency, where relative efficiency is MSE(unadjusted) / MSE(adjusted).
When comparing the adjusted estimators, adjusting for only the baseline CDR-SB
score resulted in the smallest gain in precision over using the unadjusted estimator
when baseline variables are prognostic (reduction in required sample size ranging
from -0.2% to 7.7%). Adjusting for all M candidate prognostic baseline variables
resulted in the largest precision loss when baseline variables are not prognostic (sample
size reduction ranging from -17.3% to -16.1%) and performed similarly to the three
variable selection procedures when baseline variables are prognostic. As we highlight
further below, in all scenarios with prognostic baseline variables, the lasso procedure
resulted in the largest precision gains, and in all scenarios with the no prognostic
baseline variables, the lasso procedure resulted in the smallest precision loss.
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4.2 Pre-selecting baseline variables
4.2.1 Selected baseline variables
Table 1: Baseline variables that get pre-selected from weakly correlated data (dataset 1)
with a positive marginal treatment effect.
Prognostic Variables No Prognostic Variables
Baseline Variable CV -R2 Lasso RF CV -R2 Lasso RF
CDR-SB □ □ ✓□ □ □ □
Age □ □ □ □ □ □
Female □ ✓□ □ □ □ □
Married □ □ □ □ □ □
Divorced □ ✓□ □ □ □ □
APOE4 ✓□ ✓□ □ □ □ □
MMSE □ ✓□ □ □ □ □
Logical Memory Score ✓□ ✓□ □ □ □ □
Modified Hashinski □ □ ✓□ □ □ □
Geriatric Depression Scale Total □ □ □ □ □ □
Category Fluency (Animals) □ ✓□ □ □ □ □
Trail Making Test A □ □ ✓□ □ □ □
Trails A Errors of Commission ✓□ ✓□ ✓□ □ □ □
Trail Making Test B ✓□ ✓□ □ ✓□ □ □
Trails B Errors of Commission □ □ □ □ □ □
Trails B Errors of Omission □ ✓□ ✓□ □ □ ✓□
ADAS Cog 11 item score □ □ ✓□ □ □ ✓□
ADAS Cog 13 item score ✓□ ✓□ ✓□ □ □ ✓□
RAVLT Delay □ ✓□ □ □ □ □
RAVLT Recognition □ □ □ □ □ □
FAQ □ □ □ □ □ □
For scenarios D1 and D2/D21, we mimicked the planning phase of the HOPE4MCI
trial by applying our baseline variable selection procedures to the first and second
ADNI datasets, respectively, representing scenarios where baseline variables are weakly
or strongly prognostic for the outcome. Table 1 and Table 2 display the baseline
variables that were selected using each selection procedure. Regardless of the scenario,
the variable selection procedures select very similar baseline variables for simulations
with no (results not shown) or positive marginal treatment effect (Table 1 and 2).
The variable selection procedures differ in the total number of variables selected and
16
Table 2: Baseline variables are pre-selected from strongly correlated data (dataset 2) with
a positive marginal treatment effect.
Prognostic Variables No Prognostic Variables
Baseline Variable CV -R2 Lasso RF CV -R2 Lasso RF
CDR-SB ✓□ ✓□ □ □ □ ✓□
Age □ □ □ □ □ □
Female □ □ □ □ □ □
Married ✓□ ✓□ □ □ □ □
Divorced □ □ □ □ □ □
APOE4 ✓□ ✓□ □ □ □ □
MMSE □ ✓□ ✓□ □ □ □
Logical Memory Score ✓□ ✓□ □ □ □ □
Modified Hashinski □ ✓□ □ □ □ □
Geriatric Depression Scale Total □ ✓□ □ □ □ □
Category Fluency (Animals) □ □ □ □ □ ✓□
Trail Making Test A □ □ □ ✓□ □ □
Trails A Errors of Commission □ ✓□ ✓□ □ □ □
Trail Making Test B ✓□ ✓□ □ □ □ □
Trails B Errors of Commission □ □ □ ✓□ □ □
Trails B Errors of Omission □ ✓□ □ □ □ □
ADAS Cog 11 item score □ ✓□ ✓□ □ □ ✓□
ADAS Cog 13 item score ✓□ ✓□ ✓□ □ □ □
RAVLT Delay □ ✓□ ✓□ □ □ □
RAVLT Recognition □ □ □ □ □ □
FAQ ✓□ ✓□ □ □ □ □
which variables were selected.
When pre-selecting variables under a positive marginal treatment effect and weakly
prognostic baseline variables (dataset 1), the CV -R2, lasso and RF procedures selected
5, 11 and 7 baseline variables, respectively (Table 1). The lasso procedure selected:
female, divorced, APOE4, MMSE, Logical Memory Delayed Recall Score, Category
Fluency (Animals) - Total Correct, Trails A Errors of Commission, Trial Making
Test Part B - Time to complete, Trails B Errors of Omission, ADAS Cog 13 Item
score, and RAVLT Delay. The CV -R2 procedure selected 5 of the 11 variables that
the lasso procedure selected (APOE4, Logical Memory Score, Trails A Errors of
Commission, Trail Making Test B, and ADAS Cog 13 item score); where as only
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3 variables were in common when comparing the lasso and RF procedures (Trail A
Errors of Commission, Trails B Errors of Omission and ADAS COG 13 item score).
The RF procedure selected baseline CDR-SB score, Modified Hashinski, Trail Making
Test A and ADAS COG 11 item score, all which were not selected by the other two
procedures. When pre-selecting variables under positive marginal treatment effect
and no prognostic baseline variables, the CV -R2, lasso and RF procedure choose 1,
0, and 3 baseline variables, respectively. The CV -R2 procedure selected the Trail
Making Test B and the RF procedure selected Trails B Errors of Omission and the
ADAS COG 11 and ADAS COG 13.
When pre-selecting variables from dataset 2, a slightly different pattern emerged
(Table 2). Under a positive marginal treatment effect with strongly prognostic
baseline variables, the selection procedures ranked the same in terms of the number
of baseline variables selected: lasso (14 variables), CV -R2 (7 variables) and RF (5
variables). However, both the CV -R2 and the RF procedures selected a subset of the
variables selected by the lasso procedure, albeit a different subset. When the outcome
was scrambled to create a scenario with no prognostic baseline variables, as before
the lasso procedure selected no baseline variables and the CV -R2 and RF procedures
selected a similar number of baseline variables, 2 and 3, respectively.
4.2.2 Results of adjusting for pre-selected baseline variables
Tables 3 through 6 summarize the results of hypothetical trials that adjust for pre-
selected baseline variables from D1 and D2, as described above. Adjusting for baseline
variables selected from the CV -R2, lasso, and RF procedures, as well as including
all M candidate baseline variables, resulted in large reductions in required sample
sizes when compared to the unadjusted estimator. The magnitude of the reduction
in required sample size is a function of the strength of the correlation between the
outcome and baseline variables, with greater reductions in required sample sizes when
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Table 3: Baseline variables prognostic are pre-selected with no marginal treatment effect.
Comparison of the bias, variance, mean squared error and 95% coverage probability for the
marginal treatment effect based on 10,000 hypothetical trials for estimator. The ˆ︂R2n is the
relative reduction in required sample size when using an adjusted estimator compared to
the unadjusted estimator of the marginal treatment effect.
No Marginal Treatment Effect
Scenario Bias Var1 MSE2 ˆ︃R2n3 Cov4
D1
Unadj 0.004 0.084 0.084 0.0 0.949
Y0 0.004 0.084 0.084 -0.2 0.949
All Cov 0.001 0.072 0.072 14.7 0.947
CV -R2 0.002 0.070 0.070 16.3 0.948
Lasso 0.003 0.070 0.070 16.6 0.944
RF 0.002 0.072 0.072 14.0 0.949
D2
Unadj -0.001 0.072 0.072 0.0 0.948
Y0 -0.001 0.066 0.066 7.7 0.949
All Cov -0.002 0.050 0.050 29.9 0.951
CV -R2 -0.001 0.049 0.049 31.6 0.953
Lasso -0.002 0.049 0.049 31.9 0.951
RF -0.002 0.060 0.060 16.4 0.951
D21
Unadj 0.004 0.084 0.084 0.0 0.949
Y0 0.004 0.084 0.084 -0.2 0.949
All Cov 0.001 0.072 0.072 14.7 0.947
CV -R2 0.002 0.072 0.072 14.1 0.947
Lasso 0.002 0.070 0.070 16.5 0.947
RF 0.004 0.075 0.075 11.2 0.950
1 Var corresponds to variance
2 MSE corresponds to mean squared error= variance +
bias2
3 ˆ︃R2n corresponds to the relative reduction in required
sample size comparing the adjusted estimator to the
unadjusted estimator, 1 − MSE(adjusted)
MSE(unadjusted)
4 Cov corresponds to coverage probability
the trial data includes strongly prognostic baseline variables (dataset 2) compared to
weakly prognostic baseline variables (dataset 1). Within each scenario, adjusting for
baseline variables selected from the lasso procedure yields the greatest reduction in
required sample size when compared to the unadjusted estimator (roughly 15% or 30%
reduction in required sample size when there is weak or strong correlation between
baseline variables and the outcome, respectively). For example, in simulations with
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Table 4: Baseline variables prognostic are pre-selected with a marginal treatment effect.
Comparison of the bias, variance, mean squared error and 95% coverage probability for the
marginal treatment effect based on 10,000 hypothetical trials for estimator. The ˆ︂R2n is the
relative reduction in required sample size when using an adjusted estimator compared to
the unadjusted estimator of the marginal treatment effect.
Marginal Treatment Effect
Scenario Bias Var1 MSE2 ˆ︃R2n3 Cov4
D1
Unadj -0.001 0.062 0.062 0.0 0.949
Y0 -0.001 0.062 0.062 -0.2 0.952
All Cov 0.005 0.054 0.054 13.3 0.945
CV -R2 0.002 0.052 0.052 16.0 0.946
Lasso 0.004 0.052 0.052 17.0 0.946
RF 0.003 0.055 0.055 12.3 0.945
D2
Unadj 0.005 0.055 0.055 0.0 0.944
Y0 0.005 0.051 0.051 7.1 0.944
All Cov 0.011 0.040 0.040 27.4 0.941
CV -R2 0.006 0.039 0.039 28.8 0.942
Lasso 0.010 0.038 0.038 29.7 0.942
RF 0.007 0.046 0.046 15.5 0.943
D21
Unadj -0.001 0.062 0.062 0.0 0.949
Y0 -0.001 0.062 0.062 -0.2 0.952
All Cov 0.005 0.054 0.054 13.3 0.945
CV -R2 -0.001 0.053 0.053 14.7 0.947
Lasso 0.003 0.053 0.053 15.5 0.944
RF 0.002 0.056 0.056 10.7 0.944
1 Var corresponds to variance
2 MSE corresponds to mean squared error= variance +
bias2
3 ˆ︃R2n corresponds to the relative reduction in required
sample size comparing the adjusted estimator to the
unadjusted estimator, 1 − MSE(adjusted)
MSE(unadjusted)
4 Cov corresponds to coverage probability
no marginal treatment effect and strongly prognostic baseline variables (dataset 2),
adjusting for the baseline variables pre-selected by the lasso procedure resulted in
largest sample size reduction (31.9%), compared to 31.6% and 16.4% sample size
reduction when adjusting for variables selected with CV -R2 and RF, respectively.
Including all M baseline variables resulted in a sample size reduction of 29.9%.
Further, when baseline variables are not prognostic, identifying baseline variables
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Table 5: Baseline variables not prognostic are pre-selected with no marginal treatment
effect. Comparison of the bias, variance, mean squared error and 95% coverage probability
for the marginal treatment effect based on 10,000 hypothetical trials for estimator. The ˆ︂R2n
is the relative reduction in required sample size when using an adjusted estimator compared
to the unadjusted estimator of the marginal treatment effect.
No Marginal Treatment Effect
Scenario Bias Var1 MSE2 ˆ︃R2n3 Cov4
D1
Unadj -0.001 0.085 0.085 0.0 0.949
Y0 -0.002 0.085 0.085 -0.5 0.950
All Cov -0.001 0.099 0.099 -17.3 0.948
CV -R2 -0.001 0.085 0.085 -0.7 0.950
Lasso -0.001 0.085 0.085 0.0 0.949
RF -0.002 0.088 0.088 -4.3 0.950
D2
Unadj -0.004 0.071 0.071 0.0 0.952
Y0 -0.004 0.072 0.072 -0.7 0.952
All Cov -0.002 0.083 0.083 -16.2 0.950
CV -R2 -0.004 0.073 0.073 -2.1 0.951
Lasso -0.004 0.072 0.072 -0.6 0.950
RF -0.004 0.073 0.073 -2.2 0.950
D21
Unadj -0.001 0.085 0.085 0.0 0.949
Y0 -0.002 0.085 0.085 -0.5 0.950
All Cov -0.001 0.099 0.099 -17.3 0.948
CV -R2 -0.001 0.086 0.086 -2.4 0.949
Lasso -0.001 0.085 0.085 -0.8 0.948
RF -0.001 0.086 0.086 -2.4 0.950
1 Var corresponds to variance
2 MSE corresponds to mean squared error= variance+bias2
3 ˆ︃R2n corresponds to the relative reduction in required
sample size comparing the adjusted estimator to the
unadjusted estimator, 1 − MSE(adjusted)
MSE(unadjusted)
using the lasso procedure yielded the smallest loss of efficiency compared to the
unadjusted estimator, a less than 1% increase in required sample size (Table 5,
Table 6). The remaining adjusted estimators can be ranked from smallest to largest
increase in required sample size when compared to the unadjusted estimator: Baseline
Y (less than 1%), CV -R2 (1 to 2%), RF (2 to 4%) and All Covariates (roughly 16%).
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Table 6: Baseline variables not prognostic are pre-selected with a marginal treatment effect.
Comparison of the bias, variance, mean squared error and 95% coverage probability for the
marginal treatment effect based on 10,000 hypothetical trials for estimator. The ˆ︂R2n is the
relative reduction in required sample size when using an adjusted estimator compared to
the unadjusted estimator of the marginal treatment effect.
Marginal Treatment Effect
Scenario Bias Var1 MSE2 ˆ︃R2n3 Cov4
D1
Unadj -0.006 0.061 0.061 0.0 0.951
Y0 -0.006 0.061 0.061 -0.7 0.951
All Cov -0.006 0.071 0.071 -16.6 0.950
CV -R2 -0.006 0.061 0.061 -0.5 0.951
Lasso -0.006 0.061 0.061 0.0 0.951
RF -0.006 0.063 0.063 -4.3 0.950
D2
Unadj -0.001 0.055 0.055 0.0 0.948
Y0 -0.001 0.055 0.055 -0.2 0.949
All Cov -0.001 0.064 0.064 -16.1 0.947
CV -R2 -0.001 0.056 0.056 -1.5 0.948
Lasso -0.001 0.055 0.055 0.0 0.948
RF -0.001 0.056 0.056 -2.4 0.948
D21
Unadj -0.006 0.061 0.061 0.0 0.951
Y0 -0.006 0.061 0.061 -0.7 0.951
All Cov -0.006 0.071 0.071 -16.6 0.950
CV -R2 -0.006 0.062 0.062 -1.3 0.951
Lasso -0.006 0.061 0.061 0.0 0.951
RF -0.006 0.062 0.062 -2.6 0.952
1 Var corresponds to variance
2 MSE corresponds to mean squared error= variance+bias2
3 ˆ︃R2n corresponds to the relative reduction in required
sample size comparing the adjusted estimator to the
unadjusted estimator, 1 − MSE(adjusted)
MSE(unadjusted)
4.3 Post-selecting baseline variables
4.3.1 Selected baseline variables
For scenarios D1 and D2, we simulate the HOPE4MCI trial where baseline variables
are selected for inclusion in estimation of the marginal treatment effect during the
analysis, assuming the baseline variables are weakly (dataset 1) or strongly (dataset
2) prognostic for the outcome. Table 7 and Table 8 display the baseline variables
that were chosen using each selection procedure. In both scenarios, the variable
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Table 7: Percentage of the 10,000 simulated trials where each post-selected baseline variable
is selected, assuming weakly prognostic baseline variables (dataset 1) with a positive
marginal treatment effect.
Prognostic Variables No Prognostic Variables
CV -R2 Lasso RF CV -R2 Lasso RF
Average Number of Variables 7.9 12.3 6.5 3.0 1.1 2.1
Baseline Variable
CDR-SB 39 48 74 14 6 9
Age 22 50 3 15 6 2
Female 34 56 2 14 6 1
Married 26 45 4 14 5 2
Divorced 18 55 3 17 5 4
APOE4 76 78 21 15 6 11
MMSE 30 56 26 13 5 12
Logical Memory Score 41 68 17 14 6 3
Modified Hashinski Score 19 48 36 16 6 4
Geriatric Depression Scale Total 17 42 50 15 6 11
Category Fluency (Animals) 49 68 21 14 6 15
Trail Making Test A 20 42 24 14 6 2
Trails A Errors of Commission 59 83 91 17 6 16
Trail Making Test B 68 85 30 12 5 5
Trails B Errors of Commission 27 48 6 15 5 3
Trails B Errors of Omission 29 61 82 18 5 32
ADAS Cog 11 item score 23 34 92 10 4 36
ADAS Cog 13 Item score 80 86 26 7 3 15
RAVLT Delay 52 82 38 13 5 13
RAVLT Recognition 34 48 2 13 5 7
FAQ 24 45 14 15 6 1
selection procedures choose similar baseline variables for simulations with no or a
positive treatment effect. The average number of variables selected over all 10,000
simulations and which variables selected in each simulation differ across the variable
selection procedures.
When post-selecting baseline variables in scenario D1 with weakly prognostic
baseline variables and a positive marginal treatment effect, the average number of
baseline variables chosen over the 10,000 hypothetical trials was 7.9, 12.3, and 6.5 for
the CV -R2, lasso, and RF procedures, respectively (Table 7). The 12 most frequently
selected variables in the lasso procedure were (in order of most to least frequently
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Table 8: Percentage of the 10,000 simulated trials where each post-selected baseline variable
is selected, assuming strongly prognostic baseline variables (dataset 2) with a positive
marginal treatment effect.
Prognostic Variables No Prognostic Variables
CV -R2 Lasso RF CV -R2 Lasso RF
Average Number of Variables 8.5 13.7 6.5 3.0 1.2 2.0
Baseline Variable
CDR-SB 46 73 47 13 6 12
Age 19 48 1 15 6 2
Female 20 42 3 14 6 2
Married 52 73 0 13 6 2
Divorced 26 42 13 15 6 4
APOE4 78 88 12 14 6 9
MMSE 39 65 59 14 6 11
Logical Memory Score 84 96 4 14 6 4
Modified Hashinski Score 41 71 4 15 6 6
Geriatric Depression Scale Total 24 59 10 16 7 12
Category Fluency (Animals) 25 52 33 14 6 15
Trail Making Test A 16 41 2 14 6 3
Trails A Errors of Commission 36 74 87 17 6 16
Trail Making Test B 76 92 9 12 5 6
Trails B Errors of Commission 24 48 4 14 5 4
Trails B Errors of Omission 25 71 80 18 6 25
ADAS Cog 11 item score 26 73 94 11 4 29
ADAS Cog 13 Item score 77 61 8 8 4 13
RAVLT Delay 19 60 25 13 5 12
RAVLT Recognition 23 44 90 13 5 10
FAQ 73 95 15 14 6 1
selected): ADAS Cog 13 item score (86%), Trail Making Test B (85%), Trails A
Errors of Commission (83%), RAVLT Delay (82%), APOE4 (78%), Category Fluency
(Animals) (68%), Logical Memory Delayed Recall Score (68%), Trails B Errors of
Omission (61%), Female (56%), MMSE (56%), Divorced (55%), and age (50%). The
CV -R2 procedure selected 7 of the 8 variables that the lasso selected (ADAS Cog 13
item score (80%), APOE4 (76%), Trail Making Test B (68%), Trail Making Errors of
Commission (59%), RAVLT Delay (52%), Category Fluency (Animals) (49%), Logical
Memory Delayed Recall Score (41%)); while the RF only had 3 variables in common
with the lasso (Trails A Errors of Commission (91%), Trails B Errors of Omission
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(83%), and RAVLT Delay (38%)). The RF also selected ADAS Cog 11 item score
(92%), baseline CDR-SB (74%), and Geriatric Depression Scale Total (50%).
When simulating no prognostic baseline variables under post-selecting baseline
variables with a positive marginal treatment effect, the average number of baseline
variables the CV -R2, lasso, and RF procedures choose over all the hypothetical
trials is 3.0, 1.1, and 2.2, respectively. The most frequently selected variables in
the CV -R2 procedure were the Trails B Errors of Omission (17.8%), Trails A Errors
of Commission (17%), and Geriatric Depression Scale Total (16%), while the lasso
selected the Modified Hashinski Total Score (6%), and the RF chose ADAS Cog item
11 score (36.3%) and Trails B Errors of Omission (33%).
Compared to post-selecting variables from scenario D1 with a positive marginal
treatment effect and weakly prognostic baseline variables, when post-selecting variables
in scenario D2 with a positive marginal treatment effect and strongly prognostic
baseline variables (Table 8), the CV -R2 and lasso variable selection procedures select
1 additional variable on average, and the RF selects roughly the same number of
variables on average. The CV -R2 and RF procedures selected a subset of the most
frequently selected variables by the lasso, albeit a different subset. When the outcome
was scrambled to create a scenario with no prognostic baseline variables, as expected
the average number of baseline variables chosen is the same as in pre-selecting scenario
D1 with no prognostic baseline variables.
4.3.2 Results of adjusting for post-selected baseline variables
Table 9 and Table 10 summarize the results of the hypothetical trials for scenarios D1
and D2, where prognostic baseline variables are post-selected. Similar to adjusting
for pre-selected baseline variables, adjusting for post-selected baseline variables using
the CV -R2, lasso, and RF procedures, as well as including all the M covariates,
produce large gains in efficiency when compared to the unadjusted estimator. The
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Table 9: Baseline variables prognostic are post-selected with no marginal treatment effect.
Comparison of the bias, variance, mean squared error and 95% coverage probability for the
marginal treatment effect based on 10,000 hypothetical trials for estimator. The ˆ︂R2n is the
relative reduction in required sample size when using an adjusted estimator compared to
the unadjusted estimator of the marginal treatment effect.
No Marginal Treatment Effect
Scenario Bias Var1 MSE2 ˆ︃R2n3 Cov4
D1
Unadj 0.004 0.084 0.084 0.0
Y0 0.004 0.084 0.084 -0.2 0.949
All Cov 0.001 0.072 0.072 14.7 0.947
CV -R2 0.003 0.073 0.073 13.6 0.933
Lasso 0.002 0.066 0.066 21.2 0.949
RF 0.002 0.073 0.073 13.6 0.948
D2
Unadj -0.001 0.072 0.072 0.0 0.948
Y0 -0.001 0.066 0.066 7.7 0.949
All Cov -0.002 0.050 0.050 29.9 0.951
CV -R2 -0.001 0.051 0.051 28.7 0.940
Lasso -0.002 0.047 0.047 34.8 0.951
RF -0.002 0.056 0.056 21.4 0.952
1 Var corresponds to variance
2 MSE corresponds to mean squared error= variance +
bias2
3 ˆ︃R2n corresponds to the relative reduction in required
sample size comparing the adjusted estimator to the
unadjusted estimator, 1−MSE(adjusted)
MSE(unadjusted)
4 Cov corresponds to coverage probability
lasso procedure yields the greatest efficiency gains when compared to the unadjusted
estimator (about 20% or 31-35% reduction in sample size when there is weak or
strong correlation between baseline variables and the outcome, respectively). The
CV -R2 procedure and including all the M covariates result in similar sample size
reduction of about 13-15% and 27-30%, and adjusting for variables selected by the
RF procedure yields the smallest sample size reduction of roughly 13% and 19-21%
when post-selected from dataset 1 and dataset 2, respectively.
When post-selecting baseline variables with no prognostic baseline variables (Table 11,
Table 12), adjusting for baseline variables selected by the lasso procedure results in no
greater than a 0.2% increase in required sample size. The RF procedure resulted in
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Table 10: Baseline variables prognostic are post-selected with a marginal treatment effect.
Comparison of the bias, variance, mean squared error and 95% coverage probability for the
marginal treatment effect based on 10,000 hypothetical trials for estimator. The ˆ︂R2n is the
relative reduction in required sample size when using an adjusted estimator compared to
the unadjusted estimator of the marginal treatment effect.
Marginal Treatment Effect
Scenario Bias Var1 MSE2 ˆ︃R2n3 Cov4
D1
Unadj -0.001 0.062 0.062 0.0 0.949
Y0 -0.001 0.062 0.062 -0.2 0.952
All Cov 0.005 0.054 0.054 13.3 0.945
CV -R2 0.004 0.055 0.055 12.5 0.928
Lasso 0.022 0.050 0.050 19.4 0.941
RF 0.005 0.054 0.055 12.5 0.945
D2
Unadj 0.005 0.055 0.055 0.0 0.944
Y0 0.005 0.051 0.051 7.1 0.944
All Cov 0.011 0.040 0.040 27.4 0.941
CV -R2 0.008 0.040 0.040 26.5 0.929
Lasso 0.028 0.037 0.038 30.8 0.940
RF 0.010 0.044 0.045 18.6 0.942
1 Var corresponds to variance
2 MSE corresponds to mean squared error= variance +
bias2
3 ˆ︃R2n corresponds to the relative reduction in required
sample size comparing the adjusted estimator to the
unadjusted estimator, 1−MSE(adjusted)
MSE(unadjusted)
4 Cov corresponds to coverage probability
roughly a 1-2% increase in required sample size while the CV -R2 procedure resulted
in roughly a 7-8% increase in required sample size. Including all the M covariates
yielded the greatest loss of precision, i.e. increase in required sample size of roughly
16-17%.
4.4 Comparing the timing of baseline variable selection
The results of our simulations were qualitatively similar when comparing the performance
of the baseline variable adjusted marginal treatment effects to the unadjusted estimator
when baseline variables are pre- or post-selected. There was no inflation in Type I
error due to selecting baseline variables during the analysis compared to prior to
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Table 11: Baseline variables not prognostic are post-selected with no marginal treatment
effect. Comparison of the bias, variance, mean squared error and 95% coverage probability
for the marginal treatment effect based on 10,000 hypothetical trials for estimator. The ˆ︂R2n
is the relative reduction in required sample size when using an adjusted estimator compared
to the unadjusted estimator of the marginal treatment effect.
No Marginal Treatment Effect
Scenario Bias Var1 MSE2 ˆ︃R2n3 Cov4
D1
Unadj -0.001 0.085 0.085 0.0 0.949
Y0 -0.002 0.085 0.085 -0.5 0.950
All Cov -0.001 0.099 0.099 -17.3 0.948
CV -R2 0.000 0.091 0.091 -7.2 0.937
Lasso -0.001 0.084 0.084 1.1 0.948
RF -0.001 0.086 0.086 -1.4 0.950
D2
Unadj -0.004 0.071 0.071 0.0 0.952
Y0 -0.004 0.072 0.072 -0.7 0.952
All Cov -0.002 0.083 0.083 -16.2 0.950
CV -R2 -0.003 0.077 0.077 -8.0 0.938
Lasso -0.004 0.070 0.070 1.0 0.951
RF -0.004 0.072 0.072 -0.8 0.952
1 Var corresponds to variance
2 MSE corresponds to mean squared error= variance+bias2
3 ˆ︃R2n corresponds to the relative reduction in required
sample size comparing the adjusted estimator to the
unadjusted estimator, 1 − MSE(adjusted)
MSE(unadjusted)
4 Cov corresponds to coverage probability
the trial. When using the CV -R2 procedure, there was a roughly 3% larger gain in
precision when baseline variables are prognostic and a roughly 5% smaller precision
loss when baseline variables are not prognostic, when pre- compared to post-selecting
baseline variables. When using the lasso procedure, there was a roughly 3% greater
precision gain when selecting variables during the analysis compared to selecting
variables prior to the trial. There is no difference between the precision gains when
comparing the timing of the baseline variable selection using the RF procedure.
Overall, the differences mentioned are small and there does not seem to be a clear
advantage between pre-selecting and post-selecting baseline variables.
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Table 12: Baseline variables not prognostic are post-selected with a marginal treatment
effect. Comparison of the bias, variance, mean squared error and 95% coverage probability
for the marginal treatment effect based on 10,000 hypothetical trials for estimator. The ˆ︂R2n
is the relative reduction in required sample size when using an adjusted estimator compared
to the unadjusted estimator of the marginal treatment effect.
Marginal Treatment Effect
Scenario Bias Var1 MSE2 ˆ︃R2n3 Cov4
D1
Unadj -0.006 0.061 0.061 0.0 0.951
Y0 -0.006 0.061 0.061 -0.7 0.951
All Cov -0.006 0.071 0.071 -16.6 0.950
CV -R2 -0.006 0.065 0.065 -6.7 0.939
Lasso 0.002 0.060 0.060 1.1 0.950
RF -0.006 0.062 0.062 -1.8 0.950
D2
Unadj -0.001 0.055 0.055 0.0 0.948
Y0 -0.001 0.055 0.055 -0.2 0.949
All Cov -0.001 0.064 0.064 -16.1 0.947
CV -R2 -0.001 0.059 0.059 -7.7 0.934
Lasso 0.011 0.055 0.055 -0.2 0.945
RF -0.000 0.056 0.056 -1.5 0.947
1 Var corresponds to variance
2 MSE corresponds to mean squared error= variance+bias2
3 ˆ︃R2n corresponds to the relative reduction in required
sample size comparing the adjusted estimator to the
unadjusted estimator, 1 − MSE(adjusted)
MSE(unadjusted)
4 Cov corresponds to coverage probability
5 Discussion
Based on the results of our simulation study, adjusting for baseline variables selected
using the lasso procedure resulted in the largest precision gains for the marginal
treatment effect, when baseline variables were prognostic for the outcome. When
baseline variables were not prognostic for the outcome, the lasso procedure identified
the fewest baseline variables for inclusion in the adjusted estimator resulting in the
smallest loss in precision for the marginal treatment effect.
When considering a variable selection procedure, it is important to weigh both the
advantages and disadvantages of the procedure, including complexity of implementation,
computation time, and properties of the adjusted marginal treatment effect estimator.
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Consistent with our findings, Tian et al. (2012) utilized the CV lasso procedure to
select variables to include in adjusted estimators of the marginal treatment effect
and found increased precision with superior computational efficiency compared to
other methods including forward subset selection. In a comparison of RF and other
tree-based and regression-based variable selection methods, Speiser et al. (2019)
and Sanchez-Pineto et al. (2018) both noted VSURF was among the methods that
selected the fewest variables (i.e. the most parsimonious model) and had the highest
computation times due to it’s stepwise procedure. While this was consistent with
our findings, parsimony was also a possible reason why selecting baseline variables
using VSURF did not result in as large a precision gain when compared to the lasso
procedure. In simulations with prognostic baseline variables, the lasso regression
picked roughly 12 variables on average compared to 8 for the VSURF procedure.
In addition to the choice of which baseline variable selection procedure to use,
trialists must also decide when to select the baseline variables for use in an adjusted
marginal treatment effect estimator: while planning the trial (pre-select variables) or
during the analysis of the trial data (post-select variables). The key difference in the
two approaches is that the first approach uses data available at the time of planning
the trial to a priori specify baseline variables to include in the analysis of the trial;
whereas the second approach, uses the data from the trial itself to both select baseline
variables and estimate the marginal treatment effect. One potential drawback of the
first approach is that the strength of associations between the outcome and baseline
variables observed in the data used to plan the trial may be different then those
observed in the trial data. We demonstrated this concern in simulation scenarios D2
and D21 where baseline variables were pre-selected from the second ADNI dataset,
with strongly prognostic baseline variables, during the planning phase and then
applied to subsequent trials where the baseline variables had similar prognostic power
(scenario D2) vs. weak prognostic power (scenario D21). When the correlation in the
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planning and trial data didn’t match (D21), the precision gains were reduced by as
much as 50% (similar to that achieved by pre- or post-selection under D1).
Some may interpret both the selection of baseline variables and estimation of the
marginal treatment effect during the analysis of the trial as an opening for “gaming
the system". This may be addressed by requiring that procedures are completely pre-
specified in the study protocol and statistical analysis plan and subsequently followed.
It is still important, however, to prove results on the asymptotics of the estimators
(and confidence interval procedures) that use machine learning for variable selection.
One final consideration is the target sample size for a future trial. Should trialists
assume efficiency gains from covariate adjustment and set the sample size accordingly?
As mentioned previously, if one were to assume efficiency gains from an adjusted
estimator and set the sample size based on this assumption, it is not guaranteed
that the strength of the correlation between the baseline variables and the outcome
will be similar in the trial data. If one were to assume no efficiency gains from
an adjusted estimator, then precision gains can translate into improved power if
they occur. However, one would not get any sample size reduction under the null
hypothesis in this case. An alternative would be to use information-monitoring to set
the sample size and/or trial duration; in this way, the observed correlations in the
trial are used to estimate the variance (1 divided by the information). That way, more
strongly prognostic baseline variables lead to faster information accrual and earlier
analyses, i.e., shorter trials even under the null hypothesis of no treatment effect.
Our study has several limitations. In all simulation settings, we re-sampled
(W,Y ) with replacement to preserve the correlation patterns observed within the
two ADNI datasets. There are certainly many alternative approaches for creating
a set of W prognostic for Y . Given that we curated the ADNI datasets to mimic
patient inclusion criteria for the HOPE4MCI trial, we feel that our simulations reflect
potential efficiency gains within a real trial setting as opposed to a setting that is
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generated for mathematical convenience. The foundation of our simulation study
was data from the ADNI study, a longitudinal cohort. Although the two datasets we
evaluated were curated to represent patients that may enroll within the HOPE4MCI
trial, our results may differ if we had conducted our simulation study using data from
previously completed AD trials, curated to match the HOPE4MCI inclusion/exclusion
criteria. Next, when pre-selecting variables, the selection procedures were applied to
the entire ADNI dataset. This gives an advantage for the pre-selection compared to
post-selected algorithms that chose variables based on a sample of 160 participants
from the entire population. Therefore, results from our pre-selection procedures may
be overly optimistic. To avoid this, we could pre-select baseline variables using a
bootstrap sample from the ADNI datasets. Further, we calculated all confidence
intervals for the coverage probabilities with the standard error from the ANCOVA
estimator, as if the selected baseline variables had been pre-specified in advance.
Though this generally performed well in our simulations, for post-selecting variables,
this method does not account for the variation in the baseline variable selection
procedures. One could alternatively apply a non-parametric bootstrap procedure
when post-selecting baseline variables.
Lastly, within the two machine learning variable selection procedures (lasso and
random forest), we used the default settings specified in their respective R packages.
Our results may be different if we first optimized these tuning parameters, e.g.
adjusting the number of variables randomly sampled as candidates at each split in a
RF or the tuning parameter of a lasso. Highly customizable algorithms could provide
additional flexibility that could further improve precision of the marginal treatment
effect and was not tested in our simulations. We have demonstrated the potential for
substantial precision gains for the estimates of marginal treatment effects in AD trials
Trialists should pre-specify the pool of candidate variables, selection procedures, and
adjusted marginal treatment effect estimator.
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